Skip to content

Study · Randomized controlled trial · 2024

6 results

Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program.

Zeitler P, Galindo RJ, Davies MJ, Bergman BK, Thieu VT, Nicolay C, Allen S, Heine RJ, Lee CJ

Diabetes care1 Jun 2024Cited by 11 (Europe PMC)

PMID38639997 (opens in a new tab)PMCIDPMC11116907 (opens in a new tab)DOI10.2337/dc23-2356 (opens in a new tab)PepBankPUB-38639997
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with early-onset and later-onset type 2 diabetes, tirzepatide lowered HbA1c by 2.6% and 2.4% at week 40, a similar improvement in both subgroups.

    In plain wordsIn adults with type 2 diabetes, tirzepatide lowered blood sugar (HbA1c) by a similar amount whether diabetes began early or later.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c change at week 40
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 40 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −2.6%
    early-onset
    HbA1c change
    −2.4%
    later-onset

    Source sentences

    Summary
    At week 40, similar improvements in HbA1c (-2.6% vs. -2.4%), BW (-14 vs. -13 kg), WC (-10 vs. -10 cm), triglycerides (-26% vs. -24%), HDL (7% vs. 7%), and systolic BP (-6 vs. -7 mmHg) were observed in both subgroups with tirzepatide.
    1 context sentence
    Summary · context
    We evaluated baseline characteristics of participants with early-onset type 2 diabetes (T2D) from the SURPASS program and tirzepatide's effects on glycemic control, body weight (BW), and cardiometabolic markers.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with early-onset and later-onset type 2 diabetes, tirzepatide reduced body weight by 14 kg and 13 kg at week 40, a similar improvement in both subgroups.

    In plain wordsIn adults with type 2 diabetes, tirzepatide lowered body weight by a similar amount whether diabetes began early or later.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight change at week 40
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 40 weeksAs given in this study (human).

    Measurements

    Body weight change
    −14 kg
    early-onset
    Body weight change
    −13 kg
    later-onset

    Source sentences

    Summary
    At week 40, similar improvements in HbA1c (-2.6% vs. -2.4%), BW (-14 vs. -13 kg), WC (-10 vs. -10 cm), triglycerides (-26% vs. -24%), HDL (7% vs. 7%), and systolic BP (-6 vs. -7 mmHg) were observed in both subgroups with tirzepatide.
    1 context sentence
    Summary · context
    We evaluated baseline characteristics of participants with early-onset type 2 diabetes (T2D) from the SURPASS program and tirzepatide's effects on glycemic control, body weight (BW), and cardiometabolic markers.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with early-onset and later-onset type 2 diabetes, tirzepatide reduced waist circumference by 10 cm in both subgroups at week 40.

    In plain wordsIn adults with type 2 diabetes, tirzepatide cut waist size by the same amount whether diabetes began early or later.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWaist circumference change at week 40
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 40 weeksAs given in this study (human).

    Measurements

    Waist circumference change
    −10 cm
    early-onset
    Waist circumference change
    −10 cm
    later-onset

    Source sentences

    Summary
    At week 40, similar improvements in HbA1c (-2.6% vs. -2.4%), BW (-14 vs. -13 kg), WC (-10 vs. -10 cm), triglycerides (-26% vs. -24%), HDL (7% vs. 7%), and systolic BP (-6 vs. -7 mmHg) were observed in both subgroups with tirzepatide.
    1 context sentence
    Summary · context
    We evaluated baseline characteristics of participants with early-onset type 2 diabetes (T2D) from the SURPASS program and tirzepatide's effects on glycemic control, body weight (BW), and cardiometabolic markers.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with early-onset and later-onset type 2 diabetes, tirzepatide lowered triglycerides by 26% and 24% at week 40, a similar improvement in both subgroups.

    In plain wordsIn adults with type 2 diabetes, tirzepatide lowered blood triglycerides by a similar amount whether diabetes began early or later.

    Peptide
    Tirzepatide
    Outcome
    DecreaseTriglyceride change at week 40
    Study

    n: not reported in source

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated · 40 weeksAs given in this study (human).

    Measurements

    Triglyceride change
    −26%
    early-onset
    Triglyceride change
    −24%
    later-onset

    Source sentences

    Summary
    At week 40, similar improvements in HbA1c (-2.6% vs. -2.4%), BW (-14 vs. -13 kg), WC (-10 vs. -10 cm), triglycerides (-26% vs. -24%), HDL (7% vs. 7%), and systolic BP (-6 vs. -7 mmHg) were observed in both subgroups with tirzepatide.
    1 context sentence
    Summary · context
    We evaluated baseline characteristics of participants with early-onset type 2 diabetes (T2D) from the SURPASS program and tirzepatide's effects on glycemic control, body weight (BW), and cardiometabolic markers.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with early-onset and later-onset type 2 diabetes, tirzepatide raised HDL by 7% in both subgroups at week 40.

    In plain wordsIn adults with type 2 diabetes, tirzepatide raised HDL cholesterol by the same amount whether diabetes began early or later.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHDL cholesterol change at week 40
    Study

    n: not reported in source

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated · 40 weeksAs given in this study (human).

    Measurements

    HDL change
    7%
    early-onset
    HDL change
    7%
    later-onset

    Source sentences

    Summary
    At week 40, similar improvements in HbA1c (-2.6% vs. -2.4%), BW (-14 vs. -13 kg), WC (-10 vs. -10 cm), triglycerides (-26% vs. -24%), HDL (7% vs. 7%), and systolic BP (-6 vs. -7 mmHg) were observed in both subgroups with tirzepatide.
    1 context sentence
    Summary · context
    We evaluated baseline characteristics of participants with early-onset type 2 diabetes (T2D) from the SURPASS program and tirzepatide's effects on glycemic control, body weight (BW), and cardiometabolic markers.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with early-onset and later-onset type 2 diabetes, tirzepatide lowered systolic BP by 6 and 7 mmHg at week 40, a similar improvement in both subgroups.

    In plain wordsIn adults with type 2 diabetes, tirzepatide lowered systolic blood pressure by a similar amount whether diabetes began early or later.

    Peptide
    Tirzepatide
    Outcome
    DecreaseSystolic blood pressure change at week 40
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 40 weeksAs given in this study (human).

    Measurements

    Systolic BP change
    −6 mmHg
    early-onset
    Systolic BP change
    −7 mmHg
    later-onset

    Source sentences

    Summary
    At week 40, similar improvements in HbA1c (-2.6% vs. -2.4%), BW (-14 vs. -13 kg), WC (-10 vs. -10 cm), triglycerides (-26% vs. -24%), HDL (7% vs. 7%), and systolic BP (-6 vs. -7 mmHg) were observed in both subgroups with tirzepatide.
    1 context sentence
    Summary · context
    We evaluated baseline characteristics of participants with early-onset type 2 diabetes (T2D) from the SURPASS program and tirzepatide's effects on glycemic control, body weight (BW), and cardiometabolic markers.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.